Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Chicken Egg Yolk Antibodies (IgY) for Prophylaxis and Treatment of Rotavirus Diarrhea in Human and Animal Neonates: A Concise Review.

Posted by on in 2017
  • Font size: Larger Smaller
  • Hits: 589
  • Print

Thu HM1Myat TW1Win MM1Thant KZ1Rahman S2Umeda K2Nguyen SV2Icatlo FC Jr2Higo-Moriguchi K3Taniguchi K3Tsuji T4Oguma K5Kim SJ6Bae HS6Choi HJ7. 2017. Korean J Food Sci Anim Resour. 37(1):1-9. doi: 10.5851/kosfa.2017.37.1.1. Epub 2017 Feb 28.

Department of Medical Research, No. 5, Ziwaka road, Dagon township, P.O. 11191, Yangon, Myanmar.
Immunology Research Institute in Gifu, EW Nutrition Japan, 839-7 Sano, Gifu 501-1101, Japan.
Department of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan.
Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan.
Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Dairy Team, Lotte R&D Center, 30 Seonyu-ro 9-gil, Yeongdeungpo-gu, Seoul, Korea.
BK bio, #2706-38, Iljudong-ro, Gujwa-eup, Jeju-si, Jeju-do, 63359, Korea.


The rotavirus-induced diarrhea of human and animal neonates is a major public health concern worldwide. Until recently, no effective therapy is available to specifically inactivate the rotavirion particles within the gut. Passive immunotherapy by oral administration of chicken egg yolk antibody (IgY) has emerged of late as a fresh alternative strategy to control infectious diseases of the alimentary tract and has been applied in the treatment of diarrhea due to rotavirus infection. The purpose of this concise review is to evaluate evidence on the properties and performance of anti-rotavirus immunoglobulin Y (IgY) for prevention and treatment of rotavirus diarrhea in human and animal neonates. A survey of relevant anti-rotavirus IgY basic studies and clinical trials among neonatal animals (since 1994-2015) and humans (since 1982-2015) have been reviewed and briefly summarized. Our analysis of a number of rotavirus investigations involving animal and human clinical trials revealed that anti-rotavirus IgY significantly reduced the severity of clinical manifestation of diarrhea among IgY-treated subjects relative to a corresponding control or placebo group. The accumulated information as a whole depicts oral IgY to be a safe and efficacious option for treatment of rotavirus diarrhea in neonates. There is however a clear need for more randomized, placebo controlled and double-blind trials with bigger sample size to further solidify and confirm claims of efficacy and safety in controlling diarrhea caused by rotavirus infection especially among human infants with health issues such as low birth weights or compromised immunity in whom it is most needed.


IgY; Rotavirus; diarrhea disease; neonates; oral passive immunotherapy

Last modified on